Organ Preservation Market to Reach USD 540.18 Mn by 2032 as Machine Perfusion Resets Transplant Logistics

Key Highlights

• The Organ Preservation Market was valued at USD 349.67 Mn in 2025 and is forecast to reach nearly USD 540.18 Mn by 2032, making organ viability a larger strategic priority for transplant networks and medtech firms.
• The market is expected to grow at a 6.41% CAGR from 2026 to 2032, which signals steady demand for better preservation, transport and transplant outcomes.
• Organ transplantation dominated the application segment in 2025, driven by chronic and lifestyle-related diseases causing organ failure.
• North America dominated in 2025 with nearly 45% global share, supported by healthcare infrastructure, transplant volumes, reimbursement frameworks and government initiatives.
• More than 103,000 patients were on the U.S. national transplant waiting list, while 48,129 transplants were performed in 2023, exposing a capacity gap that preservation technology must help narrow.

Why This Matters Now

Transplant systems are losing viable organs to time, logistics and preservation limits. Hospitals, payers, regulators and medtech companies now face a market where better preservation can decide who receives a life-saving transplant.

The shift matters because organ preservation is moving from static cold storage toward hypothermic and normothermic machine perfusion. These systems can extend preservation time, reduce ischemic damage and widen donor-recipient matching across distance.

Market Overview

Organ Preservation Market keeps organs viable outside the body from donor removal to recipient implantation. The goal is to protect structure and function during storage and transport, reducing ischemic damage and transplant complications.

The market is growing because organ failure cases are increasing, the elderly population is expanding and transplant procedures are rising worldwide. Static cold storage remains part of the market, but new preservation methods now include hypothermic and normothermic machine perfusion.

MMR states that many new technologies include artificial intelligence, real-time monitoring and portable logistics capabilities. That changes preservation from passive storage to active assessment, giving transplant teams more information before surgery.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/39247/

Key Trends Driving Growth

Disease burden is the first growth driver. Multiple organ failure is one of the frequent causes of ICU death and is mainly brought on by sepsis. MMR cites that up to 20% of sepsis patients show acute respiratory failure, while 26–50% develop acute renal failure. That burden raises demand for transplant-ready organs and preservation systems.

Aging is the second driver. The number of U.S. organ transplants in patients over 65 increased from 8,691 in 2019 to 8,895 in 2021. The global population aged 65 and above was 728 million in 2020 and is expected to reach 1.5 billion by 2050, increasing pressure on transplant capacity.

Healthcare investment is opening new opportunity. MMR links investment in the U.S. and South Korea to wider adoption of advanced preservation techniques, reduced tissue damage and longer organ shelf life. The business implication is clear: better infrastructure can increase organ utilization, not only improve storage.

The main barrier is cost. Organ transplantation requires surgeons, transport, inpatient care, organ procurement, preservation, post-operative care and anti-rejection drugs. For patients with limited resources, those costs compete with basic needs and can make transplant treatment inaccessible without support.

Segment Insights

• Dominant Segment Organ Transplantation: Organ transplantation dominated the application segment in 2025. The lead comes from rising chronic and lifestyle-related diseases, including diabetes, cardiovascular disorders, liver cirrhosis and kidney failure, which increase demand for transplants.
• Fastest-Growing Segment : The supplied MMR page does not identify a fastest-growing segment by organ type, solution, technique or application. No fastest-growing segment should be inferred.
• Preservation Techniques Covered: The market includes static cold storage, hypothermic machine perfusion, normothermic machine perfusion and others. The shift toward machine perfusion shows transplant centers are seeking longer preservation windows and better organ assessment.
• Organ Types Covered: The market covers kidney, heart, lung, liver, pancreas and small bowel preservation. This organ-level segmentation matters because preservation needs differ by organ type and clinical risk.
• Solutions Covered: University of Wisconsin, Custodiol HTK, Perfadex and other solutions are included in the market scope. The public page does not disclose solution-level shares.

Regional Growth Story

North America dominated the market in 2025 with nearly 45% share. MMR links that lead to advanced healthcare infrastructure, supportive government policies, high transplant rates, reimbursement frameworks and investment in transplant facilities.

The U.S. performed approximately 46,632 organ transplants in 2025, supported by hypothermic and normothermic machine perfusion. OPTN reforms also helped streamline allocation and improve donor participation, giving the U.S. a strong role in transplant logistics and clinical adoption.

Europe has direct competitive relevance. France granted regulatory derogation and reimbursement approval for XVIVO Heart Assist Transport, while the UK-based OrganOx gained U.S. FDA approval for air transport use of its metra system. Germany appears in the competitive scope through Dr. Franz Köhler Chemie.

Asia Pacific includes China, Japan, India and South Korea in the report scope. China is represented by Shanghai Genext Medical Technology, which piloted a kidney perfusion machine with a Southeast Asian hospital. South Korea is mentioned as a market where healthcare investment supports advanced preservation adoption; the public page does not provide separate Japan or India data.

Competitive Landscape

The market is highly competitive, led by TransMedics and XVIVO Perfusion AB. TransMedics has built its position around the Organ Care System, which enables normothermic preservation at warm physiologic temperatures while organs function. With more than 3,000 successful transplants worldwide, approximately 45% of the U.S. lung transplant market and revenues exceeding USD 600 Mn, TransMedics has turned transplant logistics into a platform business.

XVIVO competes through hypothermic and ex vivo perfusion technologies. Its XPS and RAPID systems, with Perfadex and Steen Solution, support kidney, lung and liver transplantation and have approvals in more than 40 countries. That signals a broader market where clinically reliable and cost-effective systems can challenge premium platform models.

Terumo’s acquisition of OrganOx for USD 477 Mn marks a major strategic entry into organ transplantation. The move signals that large medtech companies see perfusion as a growth platform, not a niche transplant accessory. Rivals will face pressure to expand portfolios through M&A, regulatory wins or transplant-center partnerships.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/39247/

Recent Developments

• XVIVO Perfusion AB, May 2026: The company secured regulatory derogation and reimbursement approval in France for XVIVO Heart Assist Transport using the HOPE method. The approval signals that reimbursement will decide how quickly advanced perfusion reaches transplant centers.
• TransMedics, April 2026: The company unveiled CHOPS, a stand-alone active cooling device designed to support clinical trials and optimize donor heart and lung preservation. The launch broadens its portfolio beyond OCS and strengthens clinical-trial infrastructure.
• Paragonix Technologies, April 2026: The company introduced TempLock technology for SherpaPak Cardiac Transport System, stabilizing preservation temperature at 4–8°C. The upgrade targets long-distance donor heart procurement.
• Terumo, October 2025: Terumo completed the acquisition of OrganOx, integrating the OrganOx metra system into its global healthcare infrastructure. The deal raises competitive pressure on specialized preservation firms.
• OrganOx, September 2025: OrganOx received U.S. FDA approval for metra system operation during air transport. The approval expands access to liver perfusion technology across longer routes.
• OrganOx, February 2025: The company secured USD 142 Mn in equity financing led by HealthQuest Capital to expand commercial reach and clinical applications. The funding signals investor confidence in normothermic machine perfusion.

Strategic Implications

For hospitals and transplant centers, preservation strategy is now a capacity lever. Machine perfusion can extend time, reduce tissue damage and improve organ assessment, helping teams convert more donated organs into usable grafts.

For medtech companies, logistics and evidence matter. Systems must prove clinical value, support reimbursement and work across transport conditions. The next phase will favor companies that combine hardware, fluids, monitoring, temperature control and clinical partnerships.

For payers and regulators, the market shifts the debate from device cost to transplant yield. Technologies that improve organ use and patient survival may gain stronger reimbursement support, as seen in France’s approval pathway for XVIVO’s heart transport system.

Future Outlook

The Organ Preservation Market is forecast to grow from USD 349.67 Mn in 2025 to nearly USD 540.18 Mn by 2032 at a 6.41% CAGR. Growth will come from rising organ failure, aging populations, transplant demand, machine perfusion, AI-enabled monitoring, healthcare investment and a persistent gap between organ demand and donations.

Future leaders will turn preservation into an active, data-rich transplant platform; laggards will remain tied to cold storage models in a market that now rewards organ viability, logistics reach and clinical proof.

Related Report

Hepatocellular Carcinoma Drugs Market: https://www.maximizemarketresearch.com/market-report/hepatocellular-carcinoma-drugs-market/74896/

Analgesics Market: https://www.maximizemarketresearch.com/market-report/analgesics-market/121475/

Digestive Enzymes Market: https://www.maximizemarketresearch.com/market-report/global-digestive-enzymes-market/36264/

Analyst Perspective

“Organ preservation is shifting from passive storage to active transplant enablement as machine perfusion, monitoring and transport innovation improve organ viability,” said Komal Patil, Analyst at Maximize Market Research. “The strongest companies will be those that connect clinical evidence, reimbursement access and logistics performance.”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com